Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Pérez Valero, Ignacio ^a   González Baeza, Alicia ^a   Estébanez, Miriam ^a   Montes Ramírez, María L ^a   Bayón, Carmen ^a   Pulido, Federico ^b   Bernardino, José I ^a   Zamora, Francisco X ^a   Monge, Susana ^c   Gaya, Francisco ^a   Lagarde, María ^b   Rubio, Rafael ^b   Hernando, Asunción ^d   Arnalich, Francisco ^a   Arribas, José R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; EDUCATION; ETHNICITY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; POLYPHARMACY; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SHORT COURSE THERAPY; SYMPTOM; TREATMENT DURATION;

ADULT; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RITONAVIR; SULFONAMIDES; VIRAL LOAD;

EID: 84880773555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069493     Document Type: Article

References (32)

1. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
2. Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, et al. (2009) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 51: 147-152.
3. Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, et al. (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24: 223-230.
4. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, et al. (2010) Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24: 2365-2374.
5. Santos JR, Moltó J, Llibre JM, Negredo E, Bravo I, et al. (2012) Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile. PLoS One 7: e37442.
6. Estébanez M, Arribas JR, (2012) Protease Inhibitor Monotherapy: What Is Its Role? (2012) Curr HIV/AIDS Rep 9: 179-185.
7. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA 308: 387-402.
8. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, et al. (2008) Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Arch Neurol 65: 65-70.
9. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR, (2011) Protease inhibitor monotherapy and the CNS: peace of mind? (2011) Journal of Antimicrobial Chemotherapy 66: 1954-1962.
10. Santos J, Muñoz-Moreno J, Molto J, Bravo I, Prats A, et al. (2012) Long-term Monotherapy with Lopinavir/ritonavir (>2 Years) Is Not Associated with Greater HIV-associated Neurocognitive Impairment. 19th Conference of Retroviruses and Opportunistic infections. Seattle, US. Abstract 483.
11. Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, et al. (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24: 2347-2354.
12. Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, et al. (2013) Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 27: 203-210.
13. Zigmond AS, Snaith RP, (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370.
14. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799.
15. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, et al. (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26: 307-319.
16. Letendre SL, FitzSimons C, Ellis RJ, Clifford D, Collier AC, et al. (2010) Correlates of CSF Viral Loads in 1221 Volunteers of the CHARTER Cohort. 17th Conference of Retroviruses and Opportunistic infections. San Francisco, US. Abstract 172.
17. Simioni S, Cavassini M, Annoni J-M, Rimbault Abraham A, Bourquin I, et al. (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24: 1243-1250.
18. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, et al. (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25: 357-365.
19. Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin c, et al. (2011) Factors influencing neurocognitive function in a large cohort of HIV infected patients on effective antiretroviral therapy. Thirteenth European AIDS Conference, Belgrade, Serbia. Abstract PS2/4.
20. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, et al. (2000) Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54: 927-936.
21. Capparelli EV, Holland D, Okamoto C, Gragg B, Durelle J, et al. (2005) Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19: 949-952.
22. Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, et al. (2009) Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Research and Human Retroviruses 25: 457-461.
23. Clifford DB, (2010) Therapeutic conundrum: AIDS therapies may be double-edged swords. Neurology 74: 1248-1249.
24. Robertson K, Liner J, Meeker RB, (2012) Antiretroviral neurotoxicity. J Neurovirol doi:10.1007/s13365-012-0120-3.
25. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, et al. (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74: 1260-1266.
26. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, et al. (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23: 1359-1366.
27. Gisslen M, Fuchs D, Hagberg L, Svennerholm B, Zetterberg H, (2012) Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis 44: 997-1000.
28. Paton NI, Meynard JL, Pulido F, Arenas-Pinto A, Girard PM, Arribas JR, (2011) Inappropriate claim of "failure of ritonavir-boosted lopinavir monotherapy in HIV in the Monotherapy Switzerland/Thailand (MOST) trial". AIDS 25: 393-394.
29. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, et al. (2010) Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy. Clinical Infectious Diseases 50: 773-778.
30. Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, et al. (2012) Cerebrospinal Fluid HIV Escape Associated with Progressive Neurologic Dysfunction in Patients on Antiretroviral Therapy with Well-Controlled Plasma Viral Load. AIDS 26: 1765-1774.
31. Winston A, Moecklinghoff C, Hill A, (2012) Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues. Int J STD AIDS 23: 225-226.
32. Panel members of the European AIDS Clinical Society (2012) European AIDS Clinical Society guidelines 2012. Version 6.1 Available: www.europeanaidsclinicalsociety.org. Accessed: 14 April 2013.